multiple sclerosis

Study Shows How Pharmaceutical Companies Maneuver To Maintain Sales, High Prices

This article is for premium subscribers. Please sign up here for a tax-deductible subscription. 

If you're a premium subscriber, sign in below. 

When a generic multiple sclerosis drug hit the U.S. market in 2015, observers expected it could push down prices in a class of drugs that has skyrocketed in recent years. 

That did not happen. 

OHSU Study: Misdiagnosis of MS is Costing Health System Millions Per Year

Study finds most MS experts surveyed have seen patients in last year who've been misdiagnosed

May 9, 2012 -- It is relatively common for doctors to diagnose someone
with multiple sclerosis when the patient doesn't have the disease — a
misdiagnosis that not only causes patients potential harm but costs the
U.S. health care system untold millions of dollars a year, according to a
study published online today in the journal Neurology.

The study is based on a survey of 122 multiple sclerosis specialists
nationwide and was conducted by researchers at Oregon Health
& Science University and the Portland Veterans Affairs Medical

Subscribe to multiple sclerosis